Cargando…
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells. Recent studies have shown that the AXL upregulation underlies epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance in EGFR-mutant non-small cell lung cancer (NSCLC). In this study, w...
Autores principales: | Jimbo, Takeshi, Hatanaka, Mana, Komatsu, Takahiro, Taira, Tomoe, Kumazawa, Kentaro, Maeda, Naoyuki, Suzuki, Takashi, Ota, Masahiro, Haginoya, Noriyasu, Isoyama, Takeshi, Fujiwara, Kosaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718264/ https://www.ncbi.nlm.nih.gov/pubmed/31497246 http://dx.doi.org/10.18632/oncotarget.27114 |
Ejemplares similares
-
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
por: Yang, James Chih-Hsin, et al.
Publicado: (2023) -
In-silico study of seaweed secondary metabolites as AXL kinase inhibitors
por: Nagamalla, Lavanya, et al.
Publicado: (2022) -
Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
por: Goto, Koichi, et al.
Publicado: (2023) -
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
por: Nakamura, Ryota, et al.
Publicado: (2023) -
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
por: Fleuren, Emmy D.G., et al.
Publicado: (2014)